Anders Månsson
Chief Executive Officer presso Anders Månsson Business Development AB
Patrimonio netto: 39 560 $ in data 31/03/2024
Profilo
Anders Månsson is currently the Chief Executive Officer at Oncoinvent AS, RhoVac ApS, and the Chief Executive Officer & Director at Mr. Månsson Business Development AB.
He is also the Chairman at CanImGuide Therapeutics AB.
Previously, he served as the Chief Executive Officer at LIDDS AB, Vice President & Head-Global Business Development at LEO Pharma A, and held various director positions at EQL Pharma AB, Respiratorius AB, and Amniotics AB.
He received his undergraduate degree from the University of Lund and his MBA from Business School Lausanne.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
EQL PHARMA AB
0.03% | 31/03/2023 | 10 000 ( 0.03% ) | 39 560 $ | 31/03/2024 |
Posizioni attive di Anders Månsson
| Società | Posizione | Inizio |
|---|---|---|
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Chairman | 01/06/2017 |
RhoVac ApS
 RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The private company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Chief Executive Officer | 02/09/2019 |
| Anders Månsson Business Development AB | Chief Executive Officer | - |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Chief Executive Officer | 01/09/2023 |
Precedenti posizioni note di Anders Månsson
| Società | Posizione | Fine |
|---|---|---|
| LIDDS AB | Chief Executive Officer | 01/08/2023 |
| AMNIOTICS AB | Chief Executive Officer | 01/01/2019 |
| EQL PHARMA AB | Chairman | 17/08/2022 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | 01/05/2017 |
| CHOSA ONCOLOGY AB | Chief Executive Officer | - |
Formazione di Anders Månsson
| University of Lund | Undergraduate Degree |
| Business School Lausanne | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| EQL PHARMA AB | Health Technology |
 | Health Technology |
| LIDDS AB | Health Technology |
| AMNIOTICS AB | Health Technology |
| Aziende private | 6 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The private company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Health Technology |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
| Anders Månsson Business Development AB |
- Borsa valori
- Insiders
- Anders Månsson
